Stroke

Hankey GJ. Stroke. Lancet (London, England). 2017; 389(10069):641–54. Epub 2016/09/18. https://doi.org/10.1016/s0140-6736(16)30962-x

Feigin VL, Nguyen G, Cercy K, Johnson CO, Alam T, Parmar PG, et al. Global, Regional, and Country- Specific Lifetime Risks of Stroke, 1990 and 2016. The New England journal of medicine. 2018; 379 (25):2429–37.Epub2018/12 /24 https://doi.org/10.1056/NEJMoa1804492

O’Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet (London, England). 2016; 388(10046):761–75. Epub 2016/07/20. https://doi.org/10.1016

Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circulation journal: official journal of the Japanese Circulation Society. 2011; 75(12):2739–48. Epub 2011/11/10. https://doi.org/10.1253/circj.cj-11-1184

Grau AJ. Infection, inflammation, and cerebrovascular ischemia. Neurology. 1997; 49(5 Suppl 4):S47– 51. Epub 1997/11/26. https://doi.org/10.1212

Goldstein LB. Novel risk factors for stroke: homocysteine, inflammation, and infection. Current athero- sclerosis reports. 2000; 2(2):110–4. Epub 2000/12/21. https://doi.org/10.1007/s11883-000-0104-2

Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis research & therapy. 2009; 11(5):249. Epub 2009/10/20. https://doi.org/10.1186/ar2758

Damasio MB, Malattia C, Martini A, Tomà P. Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatric radiology. 2010; 40(6):985–98. Epub 2010/05/01. https://doi.org/10.1007/s00247-010-1612-z

Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Seminars in arthritis and rheumatism. 2005; 35(1):8–17. Epub 2005/08/09. https://doi.org/10.1016/j.semarthrit.2005.03.004

van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP. Systemic inflammation as a riskfactor for atherothrombosis. Rheumatology (Oxford, England). 2008; 47(1):3–7. Epub 2007/08/19.https://doi.org/10.1093/rheumatology/kem202

KE B, CG H, KA T, LB M, JM H, Brady T. Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2010–2012. MMWR Morbidity and mortality weekly report. 2013;62(44):869–73.

Zaman AG, Helft G, Worthley SG, Badimon JJ. The role of plaque rupture and thrombosis in coronary artery disease. Atherosclerosis. 2000; 149(2):251–66. Epub 2000/03/24. https://doi.org/10.1016/s0021-9150(99)00479-7

Molecular Libby P. and cellular mechanisms of the thrombotic complications of atherosclerosis. Journal of lipid research. 2009; 50 Suppl(Suppl):S352–7. Epub 2008/12/20. https://doi.org/10.1194/jlr.R800099-JLR200

Altman, R.S., 2011. Chapter 35: joint disorders, In: Porter, R.S., Kaplan, J.L. (Eds.), The Merck Manual of Diagnosis and Therapy, 19th edition Merck Sharp and Dohme, Whitehouse Station, pp. 297–310.

Myasoedova, E., Crowson, C.S., Kremers, H.M., Therneau, T.M., Gabriel, S.E., 2010. Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum. 62, 1576–1582

Turesson, C., Matteson, E.L., 2004. Management of extra-articular disease manifestations İnrheumatoid arthritis. Curr. Opin. Rheumatol. 16, 206–211

ManabeI.Chronic inflammation links cardiovascular, metabolic and renal diseases. Circulation journal: official journal of the Japanese Circulation Society.2011;75(12):2739 48.Epub2011/11/10.https://doi.org/10.1253/circj.cj-11-1184

LiuW,MaW,LiuH,LiC,ZhangY,LiuJ,etal(2021)Stroke risk in arthritis:A systematic review and meta-analysis of cohort studies.PLoS ONE16(3):e0248564

Naranjo, A., Sokka, T., Descalzo, M.A., Calvo-Alén, J., Hørslev-Petersen, K., Luukkainen, R.K.,Combe, B., Burmester, G.R., Devlin, J., Ferraccioli, G., Morelli, A., Hoekstra, M., Majdan,M., Sadkiewicz, S., Belmonte, M., Holmqvist, A.C., Choy, E., Tunc, R., Dimic, A.,Bergman, M., Toloza, S., Pincus, T., QUEST-RA Group, 2008. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res. Ther. 10, R30

Goldstein JM. NeurologicComplications of RheumaticDisease. Continuum (Minneap Minn) 2014;20(3):657–669

Dakwar, E., Reddy, J., Vale, F.L., Uribe, J.S., 2008. A review of thepatho genesis of ankylosing spondylitis. Neurosurg. Focus. 24, E2. http://dx.doi.org/10.3171/FOC/2008/24/1/E2.

Szabo, S.M., Levy, A.R., Rao, S.R., Kirbach, S.E., Lacaille, D., Cifaldi, M., Maksymowych, W.P.,2011. Increased risk of cardiovascular and cerebrovascular diseases in individual swith ankylosing spondylitis: a population-based study. ArthritisRheum. 63, 3294–3304.

Nurmohamed, M.T., van der Horst-Bruinsma, I., Maksymowych, W.P., 2012. Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights. Curr. Rheumatol. Rep. 14, 415–421.

Hamdi, W., ChelliBouaziz, M., Zouch, I., Ghannouchi, M.M., Haouel, M., Ladeb, M.F., Kchir, M.M., 2012. Assessment of preclinical atherosclerosis in patients with ankylosing spondylitis. J. Rheumatol. 39, 322–326

Miranda-Filloy, J.A., Llorca, J., Carnero-López, B., González-Juanatey, C., Blanco, R., González-Gay, M.A., 2012. TNF-alpha antagonist therapy improves insulin sensitivity in non-diabetic ankylosing spondylitis patients. Clin. Exp. Rheumatol. 30, 850–855

Timlin, H., Petri, M., 2013. Transient ischemic attack and stroke in systemic lupus erythematosus. Lupus 22, 1251–1258

Futrell, N., Millikan, C., 1989. Frequency, etiology, andprevention of stroke in patients With systemic lupus erythematosus. Stroke 20, 583–591

Asherson, R.A., Khamashta, M.A., Gil, A., Vazquez, J.J., Chan, O., Baguley, E., Hughes, G.R.,1989. Cerebrovascular disease and antiphospholipid antibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome. Am. J. Med. 86, 391–399 El Maghraoui, 2011. Extra-articular manifestations of ankylosin gspondylitis: prevalence, characteristics and therapeutic implications. Eur. J. Intern. Med. 22, 554–560.

Love, P.E., Santoro, S.A., 1990. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann. Intern. Med. 112, 682–698

Levine, J.S., Branch, W., Rauch, J., 2002. Theantiphospholipidsyndrome. NEJM 346, 752–762.

Jennekens, F.G., Kater, L., 2002. The central nervous system in systemic lupus erythematosus. Part 2. Pathogenetic mechanisms of clinical syndromes: a literature investigation. Rheumatology (Oxford) 41, 619–630

Bhattacharyya S ve Helfgott SM. Neurologic Complications of Systemic Lupus Erythematosus, Sjögren Syndrome, and RheumatoidArthritis. Semin Neurol2014;34:425–436.

Zachariae, H., 2003. Prevalence of joint disease in patients with psoriasis: implicationsfortherapy. Am. J. Clin. Dermatol. 4, 441–447.

Eder, L., Thavaneswaran, A., Chandran, V., Cook, R., Gladman, D.D., 2014. Increased burden of inflammation over time is associated witht he extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2014-205267.

Denton CP, Khanna D: Systemicsclerosis . Lancet. 2017, 7:1685-1699. 10.1016/S0140-6736(17)30933-9

Orlandi M, Barsotti S, Lepri G, et al.: One year in review 2018: systemic sclerosis . Clin Exp Rheumatol. 2018 Aug, 36:3-23

Cannarile F, Valentini V, Mirabelli G, et al.: Cardiovascular disease in systemic sclerosis . Ann Transl Med. 2015, 3:8. 10.3978/j.issn.2305-5839.2014.12.12

Al Husain A, Bruce IN: Risk factors for coronary heart disease in connective tissue diseases . TherAdvMusculoskelet Dis. 2010, 2:145-153. 10.1177/1759720X10365301

Gül, A.,Pathogenesis of Behçet’s disease: Autoinflammatory features and beyond.Seminars in Immünopathology, 2015.37(4): 413-418.

Gündüz, T., ve ark.,Laboratory and clinical correlates of brain atrophy in Neuro-Behçet's disease.J Neurol Sci, 2020.414: 116831.

Biller J ve Ferro JM. Neurological aspests of systemic diseases Part I,II,III. Handbook of Clinical Neurology 2014;119-121.

Bhattacharyya S veHelfgott SM. Neurologic Complications of Systemic Lupus Erythematosus, Sjögren Syndrome, and Rheumatoid Arthritis. Semin Neurol 2014;34:425–436.

Pawate, S.,Sarcoidosis and the nervous system.Continuum (Minneap Minn), 2020.26(3): 695-715.